000130861 001__ 130861
000130861 005__ 20240228143502.0
000130861 0247_ $$2doi$$a10.1038/srep25467
000130861 0247_ $$2pmid$$apmid:27140836
000130861 0247_ $$2pmc$$apmc:PMC4853774
000130861 037__ $$aDKFZ-2017-05939
000130861 041__ $$aeng
000130861 082__ $$a000
000130861 1001_ $$0P:(DE-He78)6c57e61dc44a62313e7075a0cefbb086$$aWerner, Simone$$b0$$eFirst author$$udkfz
000130861 245__ $$aEvaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer.
000130861 260__ $$aLondon$$bNature Publishing Group$$c2016
000130861 3367_ $$2DRIVER$$aarticle
000130861 3367_ $$2DataCite$$aOutput Types/Journal article
000130861 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522241470_30777
000130861 3367_ $$2BibTeX$$aARTICLE
000130861 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130861 3367_ $$00$$2EndNote$$aJournal Article
000130861 520__ $$aAutoantibodies against tumor-associated antigens (TAAs) have been suggested as biomarkers for early detection of gastric cancer. However, studies that systematically assess the diagnostic performance of a large number of autoantibodies are rare. Here, we used bead-based multiplex serology to simultaneously measure autoantibody responses against 64 candidate TAAs in serum samples from 329 gastric cancer patients, 321 healthy controls and 124 participants with other diseases of the upper digestive tract. At 98% specificity, sensitivities for the 64 tested autoantibodies ranged from 0-12% in the training set and a combination of autoantibodies against five TAAs (MAGEA4 + CTAG1 + TP53 + ERBB2_C + SDCCAG8) was able to detect 32% of the gastric cancer patients at a specificity of 87% in the validation set. Sensitivities for early and late stage gastric cancers were similar, while chronic atrophic gastritis, a precursor lesion of gastric cancer, was not detectable. However, the 5-marker combination also detected 26% of the esophageal cancer patients. In conclusion, the tested autoantibodies and combinations alone did not reach sufficient sensitivity for gastric cancer screening. Nevertheless, some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers.
000130861 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000130861 588__ $$aDataset connected to CrossRef, PubMed,
000130861 7001_ $$0P:(DE-He78)03c284fb24dee4c82200ce43e1e0340f$$aChen, Hongda$$b1$$udkfz
000130861 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia Anna$$b2$$udkfz
000130861 7001_ $$0P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7$$aMichel, Angelika$$b3$$udkfz
000130861 7001_ $$aKnebel, Phillip$$b4
000130861 7001_ $$aHolleczek, Bernd$$b5
000130861 7001_ $$0P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aZörnig, Inka$$b6$$udkfz
000130861 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b7$$udkfz
000130861 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b8$$udkfz
000130861 7001_ $$0P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aPawlita, Michael$$b9$$udkfz
000130861 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b10$$udkfz
000130861 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b11$$eLast author$$udkfz
000130861 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/srep25467$$gVol. 6, no. 1, p. 25467$$n1$$p25467$$tScientific reports$$v6$$x2045-2322$$y2016
000130861 909CO $$ooai:inrepo02.dkfz.de:130861$$pVDB
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c57e61dc44a62313e7075a0cefbb086$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)03c284fb24dee4c82200ce43e1e0340f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000130861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000130861 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000130861 9141_ $$y2016
000130861 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2015
000130861 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130861 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130861 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130861 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000130861 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000130861 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000130861 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130861 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130861 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130861 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130861 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000130861 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000130861 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130861 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bSCI REP-UK : 2015
000130861 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000130861 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000130861 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000130861 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x3
000130861 9201_ $$0I:(DE-He78)G010-20160331$$kG010$$lGeschäftsstelle$$x4
000130861 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lMolekulare Diagnostik Oncogener Infektionen$$x5
000130861 9201_ $$0I:(DE-He78)G182-20160331$$kG182$$lGMP Einheit  Zelluläre Therapie$$x6
000130861 980__ $$ajournal
000130861 980__ $$aVDB
000130861 980__ $$aI:(DE-He78)C070-20160331
000130861 980__ $$aI:(DE-He78)G110-20160331
000130861 980__ $$aI:(DE-He78)L101-20160331
000130861 980__ $$aI:(DE-He78)D120-20160331
000130861 980__ $$aI:(DE-He78)G010-20160331
000130861 980__ $$aI:(DE-He78)F020-20160331
000130861 980__ $$aI:(DE-He78)G182-20160331
000130861 980__ $$aUNRESTRICTED